ImageneBio, Inc.
NCM: IMALive Quote
About ImageneBio, Inc.
Healthcare
Biotechnology
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
📊 Fundamental Analysis
ImageneBio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -68.9%, which indicates that capital utilization is currently under pressure.
At a current price of $4.90, IMA currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $3.94 - $18.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$65.54M
Trailing P/E
--
Forward P/E
-1.46
Beta (5Y)
--
52W High
$18.00
52W Low
$3.94
Avg Volume
38K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App